Towards an early diagnosis of invasive candidiasis in the critically ill patient;Hacia el diagnóstico temprano de la candidiasis invasora en el paciente crítico

Revista Iberoamericana de Micologia

Volumn 29, Issue 2, 2012, Pages 71-75

  Pemán, Javier ^a   Zaragoza, Rafael ^b  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

Author keywords

Critically ill patient; Early diagnosis; Invasive candidiasis

Indexed keywords

BETA 1,3 GLUCAN; FUNGAL DNA; FUNGUS ANTIBODY; FUNGUS ANTIGEN; GERM TUBE ANTIBODY; MANNAN ANTIBODY; MANNAN ANTIGEN; UNCLASSIFIED DRUG;

CANDIDA ALBICANS; CRITICALLY ILL PATIENT; EARLY DIAGNOSIS; HUMAN; INFECTION RISK; INTENSIVE CARE; INVASIVE CANDIDIASIS; MICROBIOLOGICAL EXAMINATION; PREDICTION; PROGNOSIS; SCORING SYSTEM; SERODIAGNOSIS; SHORT SURVEY;

ALGORITHMS; CANDIDIASIS, INVASIVE; CRITICAL ILLNESS; EARLY DIAGNOSIS; HUMANS; RISK ASSESSMENT; RISK FACTORS;

CANDIDA ALBICANS;

EID: 84859083366     PISSN: 11301406     EISSN: 21739188     Source Type: Journal    
DOI: 10.1016/j.riam.2012.03.002     Document Type: Short Survey

References (46)

1. Acosta J, Catalán M, Del Palacio-Perez-Medel A, Montejo JC, De-La-Cruz-Bertolo J,Moragues MD, et al. Prospective study in critically ill non-neutropenic patients: diagnostic potential of (1,3)-beta-D-glucan assay and circulating galactomannan for the diagnosis of invasive fungal disease. Eur J Clin Microbiol Infect Dis. 2011 (En prensa).
2. Alberti C., Brun-Buisson C., Burchardi H., Martin C., Goodman S., Artigas A., et al. Epi- demiology of sepsis and infection in ICU patients from an international multicen- tre cohort study. Intensive Care Med 2002, 28:108-121.
3. Almirante B., Rodríguez D., Cuenca-Estrella M., Almela M., Sanchez F., Ayats J., et al. Epidemiology, risk factors, and prognosis of Candida parapsilosis bloodstream in- fections: case-control population-based surveillance study of patients in Barcelo- na, Spain, from 2002 to 2003. J Clin Microbiol 2006, 44:1681-1685.
4. Almirante B., Rodriguez D., Park B.J., Cuenca-Estrella M., Planes A.M., Almela M., et al. the Barcelona Candidemia Project Study Group. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: Results from population-ba- sed surveillance, Barcelona Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
5. Alvarez-Lerma F., Palomar M., León C., Olaechea P., Cerda E., Bermejo B. Colonización y/o infección fúngica en unidades de cuidados intensivos Estudio multicéntrico de 1. 562 pacientes. Med Clin (Barc) 2003, 121:161-166.
6. Ben Abraham R., Keller N., Teodorovitch N., Barzilai A., Harel R., Barzilay Z., et al. Predictors of adverse outcome from candidal infection in a tertiary care hospital. J Infect 2004, 49:317-323.
7. Blumberg H.M., Jarvis W.R., Soucie J.M., Edwards J.E., Patterson J.E., Pfaller M.A., et al. Risk factors for candidal bloodstream infections in surgical intensive care unit pa- tients: the NEMIS prospective multicenter study The National Epidemiology of Mycosis Survey. Clin Infect Dis 2001, 33:177-186.
8. Cisterna R., Ezpeleta G., Telleria O., Guinea J., Regueiro B., Garcia-Rodriguez J., et al. Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain. J Clin Microbiol 2010, 48:4200-4206.
9. Dimopoulos G., Piagnerelli M., Berre J., Salmon I., Vincent J.L. Post mortem examina- tion in the intensive care unit: still useful?. Intensive Care Med 2004, 30:2080-2085.
10. Falagas M.E., Apostolou K.E., Pappas V.D. Attributable mortality of candidemia: a sys- tematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006, 25:419-425.
11. Garey K.W., Rege M., Pai M.P., Mingo D.E., Suda K.J., Turpin R.S., et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi- institutional study. Clin Infect Dis 2006, 43:25-31.
12. Garnacho-Montero J., Amaya-Villar R., Ortiz-Leyba C., Leon C., Alvarez-Lerma F., Nolla- Salas J., et al. Isolation of Aspergillus spp. from the respiratory tract in critically ill pa- tients: risk factors, clinical presentation and outcome. Crit Care 2005, 9:R191-R199.
13. Janssen J.J., Strack van Schijndel R.J., Van der Poest Clement E.H., Ossenkoppele G.J., Thijs L.G., Huijgens P.C. Outcome of ICU treatment in invasive aspergillosis. Intensi- ve Care Med 1996, 22:1315-1322.
14. Kett D.H., Azoulay E., Echeverria P.M., Vincent J.L. Candida bloodstream infections in intensive care units: analysis of the extended prevalence of infection in intensive care unit study. Crit Care Med 2011, 39:665-670.
15. Klingspor L., Jalal S. Molecular detection and identification of Candida and Aspergi- llus spp. from clinical samples using real-time PCR. Clin Microbiol Infect 2006, 12:745-753.
16. Klingspor L., Tornqvist E., Johansson A., Petrini B., Forsum U., Hedin G. A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004, 36:52-55.
17. Leleu G., Aegerter P., Guidet B. Systemic candidiasis in intensive care units: a mul- ticenter, matched-cohort study. J Crit Care 2002, 17:168-175.
18. León C., Ruiz-Santana S., Saavedra P., Almirante B., Nolla-Salas J., álvarez-Lerma F., et al. A bedside scoring system (" Candida score" ) for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Crit Care Med 2006, 34:730-737.
19. Leon C., Ruiz-Santana S., Saavedra P., Galvan B., Blanco A., Castro C., et al. Usefulness of the " Candida score" for discriminating between Candida colonization and inva- sive candidiasis in non-neutropenic critically ill patients: a prospective multicen- ter study. Crit Care Med 2009, 37:1624-1633.
20. Lortholary O., Desnos-Ollivier M., Sitbon K., Fontanet A., Bretagne S., Dromer F. Re- cent exposure to caspofungin or fluconazole influences the epidemiology of can- didemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011, 55:532-538.
21. Maravi-Poma E., Rodriguez-Tudela J.L., De Jalon J.G., Manrique-Larralde A., Torroba L., Urtasun J., et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. Intensive Care Med 2004, 30:724-728.
22. McMullan R., Metwally L., Coyle P.V., Hedderwick S., McCloskey B., O'Neill H.J., et al. A prospective clinical trial of a real-time polymerase chain reaction assay for the diagnosis of candidemia in nonneutropenic, critically ill adults. Clin Infect Dis 2008, 46:890-896.
23. Meersseman W., Vandecasteele S.J., Wilmer A., Verbeken E., Peetermans W.E., Van Wijngaerden E. Invasive aspergillosis in critically ill patients without malignancy. Am J Respir Crit Care Med 2004, 170:621-625.
24. Mikulska M., Calandra T., Sanguinetti M., Poulain D., Viscoli C. The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: re- commendations from the Third European Conference on Infections in Leukemia. Crit Care 2010, 14:R222.
25. Mohr J.F., Sims C., Paetznick V., Rodriguez J., Finkelman M.A., Rex J.H., et al. Prospective survey of (1→3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. J Clin Microbiol 2011, 49:58-61.
26. Morgan J., Meltzer M.I., Plikaytis B.D., Sofair A.N., Huie-White S., Wilcox S., et al. Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epide- miol 2005, 26:540-547.
27. Morrell M., Fraser V.J., Kollef M.H. Delaying the empiric treatment of Candida bloods- tream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005, 49:3640-3645.
28. Nolla-Salas J., Sitges-Serra A., León-Gil C., Martínez-González J., León-Regidor M.A., Ibáñez-Lucia P., et al. Candidemia in non-neutropenic critically ill patients: analysis of prognostic factors and assessment of systemic antifungal therapy Study Group of Fungal Infection in the ICU. Intensive Care Med 1997, 23:23-30.
29. Ostrosky-Zeichner L., Alexander B.D., Kett D.H., Vazquez J., Pappas P.G., Saeki F., et al. Multicenter clinical evaluation of the (1→3) beta-D-glucan assay as an aid to diag- nosis of fungal infections in humans. Clin Infect Dis 2005, 41:654-659.
30. Ostrosky-Zeichner L., Pappas P.G., Shoham S., Reboli A., Barron M.A., Sims C., et al. Improvement of a clinical prediction rule for clinical trials on prophylaxis for in- vasive candidiasis in the intensive care unit. Mycoses 2011, 54:46-51.
31. Ostrosky-Zeichner L., Sable C., Sobel J., Alexander B.D., Donowitz G., Kan V., et al. Mul-ticenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. Eur J Clin Microbiol Infect Dis 2007, 26:271-276.
32. Parkins M.D., Sabuda D.M., Elsayed S., Laupland K.B. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species in- fections. J Antimicrob Chemother 2007, 60:613-618.
33. Patel G.P., Simon D., Scheetz M., Crank C.W., Lodise T., Patel N. The effect of time to antifungal therapy on mortality in Candidemia associated septic shock. Am J Ther 2009, 16:508-511.
34. Pemán J., Cantón E., Camarena J., Alcoba J., Echeverría J., Navarro D., et al. Variación de la epidemiologia de las fungemias y de la sensibilidad a fluconazol de los aisla- mientos en los últimos 10 años en España: resultados del estudio FUNGEMYCA. Rev Iberoam Micol 2011, 28:91-99.
35. Pemán J., Cantón E., Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005, 24:23-30.
36. Pemán J., Zaragoza R. Current diagnostic approaches to invasive candidiasis in cri- tical care settings. Mycoses 2010, 53:424-433.
37. Pemán J., Zaragoza R., Quindós G., Alkorta M., Cuétara M.S., Camarena J.J., et al. Clinical factors associated with a Candida albicans Germ Tube Antibody positive test in Intensive Care Unit patients. BMC Infect Dis 2011, 11:60.
38. Petri M.G., Konig J., Moecke H.P., Gramm H.J., Barkow H., Kujath P., et al. Epidemiology of invasive mycosis in ICU patients: a prospective multicenter study in 435 non- neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycolo- gy and Pneumonia Research. Intensive Care Med 1997, 23:317-325.
39. Piarroux R., Grenouillet F., Balvay P., Tran V., Blasco G., Millon L., et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical pa- tients. Crit Care Med 2004, 32:2443-2449.
40. Puzniak L., Teutsch S., Powderly W., Polish L. Has the epidemiology of nosocomial candidemia changed?. Infect Control Hosp Epidemiol 2004, 25:628-633.
41. Sendid B., Cotteau A., Francois N., D'Haveloose A., Standaert A., Camus D., et al. Can- didaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links. BMC Infect Dis 2006, 6:80.
42. Tortorano A.M., Pemán J., Bernhardt H., Klingspor L., Kibbler C.C., Faure O., et al. Epide- miology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Micro- biol Infect Dis 2004, 23:317-322.
43. Westh H., Lisby G., Breysse F., Boddinghaus B., Chomarat M., Gant V., et al. Multiplex real-time PCR and blood culture for identification of bloodstream pathogens in patients with suspected sepsis. Clin Microbiol Infect 2009, 15:544-551.
44. Zaragoza R., Pemán J., Quindós G., Iruretagoyena J.R., Cuétara M.S., Ramirez P., et al. Clinical significance of the detection of Candida albicans germ tube-specific anti- bodies in critically ill patients. Clin Microbiol Infect 2009, 15:592-595.
45. Zaragoza R., Peman J., Quindós G., Iruretagoyena J.R., Cuétara M.S., Ramirez P., et al. Kinetic Patterns of Candida albicans Germ Tube Antibody (CAGTA) in Critically Ill Patients: Influence on Mortality. Clin Vaccine Immunol 2009, 16:1527-1528.
46. Zilberberg M.D., Kollef M.H., Arnold H., Labelle A., Micek S.T., Kothari S., et al. Inappro- priate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study. BMC Infect Dis 2010, 10:150.